Alimta and Bleeding into the skin - a phase IV clinical study of FDA data

Summary:

Bleeding into the skin is reported as a side effect among people who take Alimta (pemetrexed disodium), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Folic Acid, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Bleeding into the skin when taking Alimta. It is created by eHealthMe based on reports of 7,644 people who have side effects when taking Alimta from the FDA, and is updated regularly.

What is Alimta?

Alimta has active ingredients of pemetrexed disodium. eHealthMe is studying from 7,702 Alimta users. Check the latest studies of Alimta.

What is Bleeding into the skin?

Bleeding into the skin is found to be associated with 937 drugs and 1,908 conditions by eHealthMe. Check the latest studies of Bleeding into the skin.

On Jul, 06, 2026

7,644 people reported to have side effects when taking Alimta.
Among them, 25 people (0.33%) have Bleeding into the skin.

Could Alimta cause Bleeding into the skin?

Among these 25 people:

How long have people been on Alimta when they have Bleeding into the skin? *

What is the gender of people who have Bleeding into the skin when taking Alimta? *

female: 32 %
male: 68 %

What is the age of people who have Bleeding into the skin when taking Alimta? *

What are other drugs people take besides Alimta? *

Folic Acid: 9 people, 36.00%
Carboplatin: 6 people, 24.00%
Cisplatin: 5 people, 20.00%
Enalapril Maleate And Hydrochlorothiazide: 3 people, 12.00%
Dexamethasone: 3 people, 12.00%
Xanax: 3 people, 12.00%
Plavix: 3 people, 12.00%
Decadron: 2 people, 8.00%
Coreg: 2 people, 8.00%
Clonidine: 2 people, 8.00%

What are other side effects people have besides Bleeding into the skin? *

Thrombocytopenia (decrease of platelets in blood): 11 people, 44.00%
Anaemia (lack of blood): 8 people, 32.00%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 8 people, 32.00%
Acute Kidney Failure: 7 people, 28.00%
Nosebleed (bleeding from nose): 6 people, 24.00%
Unilateral Hydronephrosis (kidney stone that causes obstruction of the ureter): 5 people, 20.00%
Pneumonia: 5 people, 20.00%
Weakness: 4 people, 16.00%
Stomatitis (inflammation of mucous membrane of mouth): 4 people, 16.00%
Nausea (feeling of having an urge to vomit): 3 people, 12.00%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 7 people, 28.00%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 12.00%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 3 people, 12.00%
Pleural Mesothelioma Malignant (cancer of the pleura, or the membrane that lines the lungs): 2 people, 8.00%
Lung Adenocarcinoma Metastatic (a form of non-small cell lung cancer spreads to other part): 2 people, 8.00%
Pleural Mesothelioma (cancer of the pleura, or the membrane that lines the lungs): 1 person, 4.00%
Pancreatic Neoplasm (pancreatic tumour): 1 person, 4.00%
Pain: 1 person, 4.00%
Non-Small Cell Lung Cancer Stage Iv: 1 person, 4.00%
Neoplasm Malignant (cancer tumour): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Alimta and have Bleeding into the skin?

- Check whether Bleeding into the skin is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Alimta:

Alimta (7,702 reports)

Browse all side effects of Alimta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bleeding into the skin:

Bleeding into the skin (937 drugs)

Browse all the conditions that are associated with Bleeding into the skin:

Bleeding into the skin (1,908 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pemetrexed disodium (the active ingredients of Alimta) and Alimta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.